MRK:NYE-Merck & Company Inc. (new)

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 70.78

Change

+0.80 (+1.14)%

Market Cap

USD 188.24B

Volume

6.14M

Yahoo Analyst Target

USD 71.62 (1.19%)

STA Analyst Target

USD 67.31 (-4.91%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-09-20 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.52 (+1.08%)

USD 380.90B
PFE Pfizer Inc.

+0.49 (+1.13%)

USD 256.47B
NVS Novartis AG

+1.07 (+1.26%)

USD 199.61B
ABBV AbbVie Inc.

+1.66 (+1.82%)

USD 140.34B
LLY Eli Lilly and Company

+0.33 (+0.31%)

USD 113.92B
SNY Sanofi American Depositary Sha..

+0.25 (+0.57%)

USD 109.87B
BMY Bristol-Myers Squibb Company

+0.95 (+1.56%)

USD 100.77B
GSK GlaxoSmithKline PLC

+0.32 (+0.81%)

USD 98.88B
AZN Astrazeneca PLC

+0.42 (+1.13%)

USD 95.57B
AGN Allergan plc

+4.48 (+2.38%)

USD 65.35B

ETFs Containing MRK

FTXH First Trust Nasdaq Pharma.. 8.06 % 0.60 %

+0.35 (+1.52%)

USD 5.86M
IHE iShares U.S. Pharmaceutic.. 7.97 % 0.43 %

+3.02 (+1.81%)

USD 0.47B
DJD Invesco Dow Jones Industr.. 5.93 % 0.30 %

+0.36 (+1.00%)

USD 0.01B
LIFE.B:CA Evolve Global Healthcare .. 5.27 % 0.67 %

N/A

CAD 1.04M
LIFE:CA Evolve Global Healthcare .. 5.27 % 0.66 %

N/A

CAD 1.46M
PPH VanEck Vectors Pharmaceut.. 5.20 % 0.35 %

+0.85 (+1.34%)

USD 0.28B
XLV SPDR Select Sector Fund -.. 5.12 % 0.14 %

+0.91 (+0.97%)

USD 19.03B
PJP Invesco Dynamic Pharmaceu.. 5.06 % 0.57 %

+0.84 (+1.16%)

USD 0.59B
HHL:CA Harvest Healthcare Leader.. 5.00 % 1.24 %

+0.07 (+0.81%)

CAD 0.28B
HHL.U:CA Harvest Healthcare Leader.. 5.00 % 0.00 %

+0.07 (+0.81%)

CAD 0.03B
IYH iShares U.S. Healthcare 4.79 % 0.43 %

+1.82 (+0.91%)

USD 2.32B
CNCR Loncar Cancer Immunothera.. 4.52 % 0.79 %

+0.39 (+1.58%)

USD 0.06B
FHLC Fidelity MSCI Health Care.. 4.34 % 0.08 %

+0.44 (+0.96%)

USD 1.47B
VHT Vanguard Health Care 4.33 % 0.10 %

+1.60 (+0.90%)

USD 8.83B
XPH SPDR S&P Pharmaceuticals 4.33 % 0.35 %

+0.82 (+1.71%)

USD 0.40B
RXL ProShares Ultra Health Ca.. 4.09 % 0.95 %

+1.94 (+1.73%)

USD 0.16B
VSL Volshares Large Cap 4.02 % 0.00 %

N/A

USD 0.64M
PILL Direxion Daily Pharmaceut.. 3.66 % 0.00 %

+0.84 (+2.38%)

USD 5.42M
FDL First Trust Morningstar 3.64 % 0.45 %

+0.22 (+0.74%)

USD 1.46B
IXJ iShares Global Healthcare 3.58 % 0.47 %

+0.64 (+1.03%)

USD 1.76B
EDOW First Trust Dow 30 Equal .. 3.53 % 0.50 %

+0.19 (+0.81%)

USD 5.94M
USMC Principal U.S. Mega-Cap M.. 3.29 % 0.12 %

+0.26 (+0.92%)

USD 1.61B
JHMH John Hancock Multifactor .. 3.26 % 0.50 %

+0.35 (+1.00%)

USD 0.06B
XDU:CA iShares Core MSCI US Qual.. 2.83 % 0.16 %

+0.20 (+0.93%)

CAD 0.02B
MOAT VanEck Vectors Morningsta.. 2.83 % 0.48 %

+0.42 (+0.90%)

USD 1.58B
HID:CA WisdomTree U.S. High Divi.. 2.47 % 0.41 %

+0.03 (+0.14%)

CAD 0.01B
HID.B:CA WisdomTree U.S. High Divi.. 2.47 % 0.37 %

N/A

CAD 0.01B
DHS WisdomTree U.S. High Divi.. 2.46 % 0.38 %

+0.50 (+0.69%)

USD 0.97B
HEA.U:CA Horizons Enhanced Income .. 2.35 % 0.83 %

N/A

CAD 0.03B
YLDE ClearBridge Dividend Stra.. 2.35 % 0.59 %

N/A

N/A
FLGD:CA Franklin LibertyQT Global.. 2.31 % 0.00 %

-0.12 (-0.60%)

CAD 9.90M
FLQD Franklin LibertyQ Global .. 2.29 % 0.45 %

+0.05 (+0.19%)

USD 0.02B
XDG:CA iShares Core MSCI Global .. 2.11 % 0.22 %

+0.18 (+0.90%)

CAD 0.04B
ZUH:CA BMO Equal Weight US Healt.. 2.01 % 0.39 %

+0.45 (+0.81%)

CAD 0.37B
FDRR Fidelity Dividend ETF for.. 1.94 % 0.29 %

+0.23 (+0.71%)

USD 0.38B
RNDV First Trust US Equity Div.. 1.77 % 0.50 %

+0.20 (+0.89%)

USD 4.55M
DSI iShares MSCI KLD 400 Soci.. 1.53 % 0.48 %

+1.05 (+0.98%)

USD 1.26B
DTN WisdomTree U.S. Dividend .. 1.51 % 0.38 %

+0.40 (+0.43%)

USD 0.85B
JVAL JPMorgan U.S. Value Facto.. 1.43 % 0.00 %

+0.20 (+0.73%)

N/A
RUD.U:CA RBC Quant U.S. Dividend L.. 1.38 % 0.43 %

N/A

CAD 0.04B
RUD:CA RBC Quant U.S. Dividend L.. 1.38 % 0.43 %

N/A

CAD 0.41B
JDIV JPMorgan U.S. Dividend 0.70 % 0.00 %

+0.08 (+0.31%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.79% 90% A- 91% A-
Dividend Return 2.56% 64% D 53% F
Total Return 28.35% 90% A- 92% A-
Trailing 12 Months  
Capital Gain 7.58% 70% C- 65% D
Dividend Return 2.92% 67% D+ 45% F
Total Return 10.50% 75% C 64% D
Trailing 5 Years  
Capital Gain 47.43% 72% C- 73% C
Dividend Return 19.16% 73% C 59% F
Total Return 66.59% 67% D+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 3.45% 60% D- 55% F
Dividend Return 6.66% 60% D- 50% F
Total Return 3.21% 67% D+ 58% F
Risk Return Profile  
Volatility (Standard Deviation) 13.14% 85% B 55% F
Risk Adjusted Return 50.66% 70% C- 49% F
Market Capitalization 167.96B 87% B+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 17% F 3% F
Price/Book Ratio 5.61 32% F 14% F
Price / Cash Flow Ratio 6.53 5% F 18% F
Price/Free Cash Flow Ratio 36.48 9% F 16% F
Management Effectiveness  
Return on Equity 3.87% 39% F 34% F
Return on Invested Capital 10.95% 39% F 60% D-
Return on Assets 1.53% 39% F 40% F
Debt to Equity Ratio 71.00% 50% F 51% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

MRK:NYE-Merck & Company Inc. (new)

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 70.78

Change

+0.80 (+1.14)%

Market Cap

USD 188.24B

Volume

6.14M

Yahoo Analyst Target

USD 71.62 (1.19%)

STA Analyst Target

USD 67.31 (-4.91%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-09-20